Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Active not recruiting 4Recruiting 3Not yet recruiting 2

Sponsor Class

OTHER 3NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Rhabdomyosarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1

Interventions

Specimen Handling 7Magnetic Resonance Spectroscopy 6Radiotherapy 5Biopsy 4Radiation 3Cytarabine 3Cyclophosphamide 3venetoclax 2Vincristine 2Standard of Care 2Spinal Puncture 2Practice Guidelines as Topic 2High-Energy Shock Waves 2Daunorubicin 2Azacitidine 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1taxane 1sulforaphane 1sacituzumab govitecan 1revumenib 1prednylidene 1pertuzumab 1pembrolizumab 1pegaspargase 1nelarabine 1merphos 1liposomal doxorubicin 1lenvatinib 1gilteritinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × NETWORK × Spinal Puncture × Clear all
NCT07466316 2026-03-12

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

Children's Oncology Group

Phase 3 Not yet recruiting
342 enrolled
Sarcoma

Rhabdomyosarcoma

NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡